// App-Quantinova.ai

1115 : Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)

Researchers

Presenter

  • Bruno Emond

Principal Investigators

  • Kay Sadik

  • Marie-Helene Lafeuille

  • Willy Wynant

  • Aurelie Cote-Sergent

  • Patrick Lefebvre

  • Kimberly Woodruff

Medical Centers

  • Analysis Group, Inc., Montreal, QC, Canada

  • Janssen Scientific Affairs, LLC, Titusville, NJ

  • Janssen Scientific Affairs, Horsham, PA

Locations

  • Canada

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab Biosimilar

  • Infliximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved